GENE THERAPY

摘要

A vector system is provided which comprises a first component (a) comprising a first promoter element composed of a tetracycline-regulated promoter upstream of a nucleic acid sequence encoding a first protein in which said nucleic acid sequence is upstream of a termination of transcription signal; and a second component (b) comprising a second promoter element upstream of a nucleic acid sequence encoding the reverse tetracycline transactivator (rtTA) protein rtTA2S-M2 which is upstream of an internal ribosomal entry site (IRES) which is upstream of a nucleic acid sequence which encodes the tetracycline repressor protein tetR-KRAB, which is upstream of a termination of transcription signal in which the second component (b) is present in the vector in the opposite orientation to the first component (a). Such vector systems have use in the treatment of diseases characherised by inflammation.